{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-099044","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2022-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.308622+00:00","generated_at":"2026-06-26T08:53:14.043531+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Therapeutics enters $15M upfront license deal with Jazz for WTX-613 (IFNα INDUKINE)","bullets":["Upfront payment of $15M within 10 days of signing; Jazz to reimburse pre-clinical costs.","Eligible for up to $520M in development/regulatory milestones and up to $740M in sales-based milestones.","Tiered mid-single-digit royalties on annual net sales of licensed products.","Werewolf grants Jazz worldwide exclusive license to patent rights for IFNα variants, including WTX-613.","Jazz responsible for IND submission and all subsequent development and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-099044","json":"https://secwatch.observer/filing/0001193125-22-099044.json","markdown":"https://secwatch.observer/filing/0001193125-22-099044.md","text":"https://secwatch.observer/filing/0001193125-22-099044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312522099044/0001193125-22-099044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312522099044/d335484d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:53:14.043531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}